<?xml version="1.0" encoding="UTF-8"?>
<p>As per the WHO update, dated 27 May 2020, ten vaccine candidates have entered clinical trials in different countries (
 <xref ref-type="fig" rid="biology-09-00141-f002">Figure 2</xref>). In the USA, trials have begun for an RNA vaccine, mRNA-1273 developed by the US National Institute of Allergy and Infectious Diseases (NIAID) in partnership with Moderna. An adenovirus based vaccine named Ad5-nCoV developed by CanSino Biologics (Tianjin, China), has entered clinical trials in Wuhan, China and a DNA based vaccine developed by Inovio Pharmaceuticals has entered Phase I clinical trials in South Korea [
 <xref rid="B52-biology-09-00141" ref-type="bibr">52</xref>]. Indian company Serum India Limited is also participating in a ChAdOx1-S vaccine development program. Along with 10 clinical trial candidate vaccines, another 115 candidate vaccines are in the pre-clinical stage of development as per DRAFT landscape of COVID-19 candidate vaccinesâ€”prepared by WHO, accessed on 27 May 2020 [
 <xref rid="B52-biology-09-00141" ref-type="bibr">52</xref>] (
 <xref rid="biology-09-00141-t001" ref-type="table">Table 1</xref>).
</p>
